NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells
about
Targeting DNA Replication Stress for Cancer TherapyThe Role of the COP9 Signalosome and Neddylation in DNA Damage Signaling and RepairTargeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateNew molecular targets in mantle cell lymphomaRegulation of Unperturbed DNA Replication by UbiquitylationGenomic instability in cancer.Genetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligasesRe-replication of a centromere induces chromosomal instability and aneuploidyUbiquitylation, neddylation and the DNA damage responseThe tail that wags the dog: p12, the smallest subunit of DNA polymerase δ, is degraded by ubiquitin ligases in response to DNA damage and during cell cycle progressionMutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsDistinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticityIdentification of genes that are essential to restrict genome duplication to once per cell divisionInactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.14-3-3 proteins play a role in the cell cycle by shielding cdt2 from ubiquitin-mediated degradationOvercoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924CRL1-FBXO11 promotes Cdt2 ubiquitylation and degradation and regulates Pr-Set7/Set8-mediated cellular migration.CRL4Cdt2: master coordinator of cell cycle progression and genome stabilityTargeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.Targeting the neddylation pathway to suppress the growth of prostate cancer cells: therapeutic implication for the men's cancer.MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinomaHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Protein neddylation: beyond cullin-RING ligases.Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications.The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme.The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic targetRereplication in emi1-deficient zebrafish embryos occurs through a Cdh1-mediated pathway.Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapyHepatic deficiency of COP9 signalosome subunit 8 induces ubiquitin-proteasome system impairment and Bim-mediated apoptosis in murine livers.Regulation of T cell receptor complex-mediated signaling by ubiquitin and ubiquitin-like modificationsInduction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppressionDevelopment of inhibitors in the ubiquitination cascade.Molecular targeted approaches in mantle cell lymphoma.Inactivating UBE2M impacts the DNA damage response and genome integrity involving multiple cullin ligases.
P2860
Q26739923-8CB9B0A0-5F42-4088-A0CB-B3DD7C24A12CQ26782011-29771943-1427-48DF-9055-F4505FEA820AQ26798062-B9BA3394-22DC-480F-9CF6-05A7C9A695DDQ26821766-D896144A-173F-4874-9075-5BB11DCDDBCFQ26853389-82EEB5DF-8460-40A0-A0B3-B1414963F72BQ27013707-A9746E31-D85F-4669-B41E-DE939481A41DQ27027897-3A1C072A-F0DC-4E88-99D4-47EECE843A65Q27311421-5957E5D6-C336-44EE-A235-89A16A075024Q28087342-0EDD889C-D652-4209-8E58-71603F24FDF9Q28303222-61BD314C-0369-4C07-A7F3-9E0B45381EC7Q28541763-FFD6848A-0F88-4B1B-B791-847B4C55AEF3Q28818350-6335B3B9-4039-457B-81CE-071EDCACBB36Q28820756-C56CB4A7-B9C6-4315-9DFA-98D670D20F44Q30276526-610DD39D-C051-4219-B9D7-6F869C47DC01Q30405556-98A210B3-62E7-49CD-A1C0-119BD5C39D04Q30410498-FB79A355-2133-4ACD-A56E-F6C4146D5385Q30414178-714BD216-E153-4987-8B9C-A60A7DF435FDQ30433428-6C9AD923-0F3B-46F6-A0C7-AF4D2355DD26Q30525356-58ADAD40-113C-4B7E-A3D1-993C519C9DB5Q33427510-57E32ED7-9974-4D23-ABDB-81DC0473ED89Q33714747-F791912B-DFC2-4E2F-8013-C4D4C07993FEQ33908666-CB7DDB01-80C4-4E79-A9A4-0A9AA83EA698Q33912016-39F5D5B9-E48E-4CD1-9FE2-B626EA0E9C8AQ33983255-5BDBB36D-44FC-4D7B-85D1-DD6571569966Q34042816-7C662961-5D2A-466F-93F6-A0E93AE00C2AQ34043821-3524E749-0C5A-463F-8CAC-F5CFABFFF1FFQ34212168-B1030581-4F06-4746-9E14-51AB939C16EAQ34227548-35570E30-0B1F-4057-91AB-7625586DB479Q34365897-461E5748-E1C9-408C-9792-D46494CF1EE9Q34452187-47B96B95-2FCA-42CE-A00D-ACA0D06AABAEQ34465347-3D18B2A4-FEB5-429B-A4CD-0B98770FB42FQ34521260-1D564C22-09F0-4409-B035-386CFBA0A607Q34543264-7416FF56-D388-4F86-B6F2-1C41875D01D6Q34563129-69E065EA-89FB-4FA5-9ACB-C911D9AB104DQ34809043-9252AAFF-5B9C-4E7F-B0F8-5C638810FE36Q34987659-D0050A0C-6FE4-42A6-B238-8C22195F0664Q35042995-A4121CA1-3D2F-4269-8B02-ACD33F6CB802Q35044801-F3F7FFFE-2DF2-456F-9DA7-E1B810E9C162Q35127368-90EB74DC-9A62-4757-A6C0-CA7682AA8736Q35207086-89903BE3-FA92-46C4-A25D-540AD9651775
P2860
NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@ast
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@en
type
label
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@ast
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@en
prefLabel
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@ast
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@en
P2093
P2860
P1433
P1476
NEDD8-targeting drug MLN4924 e ...... and senescence in cancer cells
@en
P2093
Jie Jessie Lin
Michael A Milhollen
Peter G Smith
Usha Narayanan
P2860
P304
10310-10320
P356
10.1158/0008-5472.CAN-10-2062
P407
P577
2010-12-01T00:00:00Z